Curated News
By: NewsRamp Editorial Staff
September 17, 2026
Regentis Biomaterials Advances GelrinC Cartilage Regeneration Implant
TLDR
- Regentis Biomaterials targets a 470,000-case U.S. knee cartilage market with GelrinC, offering a first-mover advantage in off-the-shelf regenerative implants.
- GelrinC is a liquid hydrogel cured with UV light, forming a scaffold that degrades in six to nine months as new cartilage grows.
- Regentis Biomaterials' GelrinC could restore knee cartilage without cell harvesting, potentially improving mobility and quality of life for many patients.
- GelrinC uses UV light to cure a liquid implant in place, then dissolves as the body regrows cartilage, with Phase 2 data showing four-year benefits.
Impact - Why it Matters
This news matters because it highlights a potential breakthrough in cartilage repair that could offer a less invasive, off-the-shelf solution for millions suffering from knee cartilage damage. Current treatments often require cell harvesting or extensive surgery, but GelrinC's approach could simplify the procedure and improve outcomes. With positive Phase 2 data and ongoing pivotal trials, Regentis is positioning itself to address a significant unmet need in orthopedics. If approved, GelrinC could become a first-of-its-kind treatment, reducing pain and restoring function for patients while creating a new market opportunity in regenerative medicine.
Summary
Regentis Biomaterials (NYSE American: RGNT) is making strides in regenerative medicine with its lead product GelrinC, an off-the-shelf hydrogel implant designed to regenerate damaged knee cartilage. Unlike traditional treatments that require cell harvesting or laboratory expansion, GelrinC is delivered as a liquid and cured in place using UV light, forming a temporary scaffold that gradually degrades over six to nine months. This process supports the body's natural regeneration of cartilage. The company reports encouraging Phase 2 data from 56 patients, showing sustained improvements in pain and function through four years of follow-up. Imaging has revealed regenerated tissue with characteristics resembling native hyaline cartilage. GelrinC has received CE Mark approval in Europe, and an FDA-authorized pivotal study is currently underway in the U.S. and Europe, with two-year follow-up data intended to support a Premarket Approval application.
Regentis Biomaterials is a regenerative medicine company focused on innovative tissue repair solutions, initially targeting orthopedic treatments. Its Gelrin platform technology is based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. GelrinC, a cell-free, off-the-shelf hydrogel, is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled and synchronous process. The product aims to address a market of approximately 470,000 cartilage knee repair cases annually in the U.S., where no off-the-shelf treatment is currently available. The content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid investor awareness and marketing engagement. For more information, visit https://ibn.fm/bMdpZ.
MissionIR, a specialized communications platform, assists IR firms with syndicated content to enhance visibility of private and public companies. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN, offering access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and tailored corporate communications solutions. MissionIR is powered by IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Regentis Biomaterials Advances GelrinC Cartilage Regeneration Implant
